Pharmaceutical- vs Dispensary-Sourced Cannabinoids

This program will include a discussion of investigational agents not approved by the FDA for use in the US, and data that were presented in abstract form. These data should be considered preliminary until published in a peer-reviewed journal.

Cannabis Sativa

Cannabinoid Pharmacology

History of Cannabinoid Use in Medicine

Current Legal Status of Cannabis in the United States

Cannabis-Based Drugs: DEA Schedule I

Cannabinoid Formulations Available in Medical Marijuana Dispensaries

CBD Products Available in Dispensaries

FDA Actions Regarding CBD Medical Claims

Cannabinoid Dose and Label Accuracy in Edible Medical Cannabis Products

FDA-Approved Farm for Cannabis for Research

FDA Regulation of Drugs

Routes of CBME Delivery

Currently Available Cannabinoid-Based Therapies With FDA-Approved Indications

Evidence for Efficacy of CBME Use

Evidence for Efficacy of CBME Use (cont)

Evidence for Efficacy of CBME Use (cont)

Cannabinoids in Epilepsy: Experimental Evidence

Cochrane Review of Cannabidiol in Epilepsy

CBD in the Treatment of Epilepsy: Early Studies

CBME in Epilepsy Recent Case Series and Reports With CBD

AEs Associated With CBME

Multicenter, 12-Week, Prospective, Open-Label, Purified Oral CBD Trial

Add-On Oral CBD Solution in Dravet Syndrome

Add-On Oral CBD Solution in LGS Study 1

Add-On Oral CBD Solution in LGS Study 2

Benefits of CBD Beyond Seizure Control?

Effects of CBD on Serum Levels of AEDs

Other Cannabinoids in Clinical Development for Epilepsy

Conclusions

Abbreviations

Abbreviations (cont)